OBJECTIVE: Severe acute graft-versus-host disease (aGVHD) remains a major cause of transplantation-related mortality. On the other hand, grade I aGVHD has a positive effect on survival, due to a graft-versus-leukaemia effect. Hence, a mild aGVHD is desirable. This can be achieved by means of a measured GVHD prophylaxis. Prophylaxis regimens are based on the identification of risk factors predisposing for aGVHD, which are not necessarily the same in children and adults. Therefore, such factors need to be properly evaluated. We have performed a retrospective analysis of risk factors for aGVHD in 258 consecutive patients under the age of 18 years who underwent allo-SCT at Huddinge University Hospital between 1975 and July 2000. METHODS: Thirty-nine potential risk factors were assessed with univariate analysis in a logistic regression model. Eight factors (immunised female donor to male recipient; donor age Ͼ15 years; matched unrelated donor; the absence of an HLA-identical sibling donor; AB0 disparity of any kind; estimated high risk for GVHD prior to transplant; time to engraftment; GVHD monotherapy prophylaxis) with pϽ0.10 were further evaluated in multivariate analysis, where potential risk factors were stepwise eliminated until all remaining factors were significant at the level of pϽ0.05. RESULTS: 3 independent risk factors predisposing for severe (grade II-IV) acute GVHD were found. They were 1) donor other than HLA-identical sibling (pϽ0.001); 2) monotherapy (MTX or CsA) GVHD prophylaxis (pϽ0.001); and 3) AB0 disparity of any kind (p=0.02). The risk factors were additive: Severe aGVHD was seen in none of the patients without any risk factor (n=46); in 16% with 1 risk factor (n=124); in 32% with 2 risk factors (n=82); and in 67% with all 3 risk factors (n=6) present. CONCLUSIONS: 1) AB0 blood group difference between donor and recipient is a risk factor for acute GVHD after allo-SCT in children. AB0 status should be considered when choosing between otherwise equally well matched donors.
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Incidence of and risk factors for chronic graft-versus-host disease in children given an allogeneic haematopoietic stem cell transplantation M. Zecca, A. Pession, R. Rondelli, E. Lanino, C. Uderzo, C. Messina, F. Fagioli, F. Porta, F. Locatelli, A. Prete, on behalf of the AIEOP-BMT Group (Italy)
Introduction. Chronic graft-versus-host disease (C-GVHD) remains the major cause of mortality and morbidity in long-term survivors after allogeneic haematopoietic stem cell transplant (HSCT). Previously published studies documented that this complication occurs with a lower incidence in younger patients. However, no study specifically focused on children and risk factors for C-GVHD in childhood are still poorly defined. We retrospectively analysed 702 children given allogeneic HSCT from 01/01/91 to 06/30/99, surviving at least 90 days after transplantation and reported to the AIEOP-BMT registry. Patient characteristics. 421 patients (60%) were males and 281 (40%) were females. In 458 cases (65%) the diagnosis was of malignant disease, while the remaining 244 children (35%) had a non-malignant disease. Median age at transplantation was 7 yrs (0.3-17), whereas median donor age was 12 yrs (0-55). The donor was an HLA-identical sibling in 471 cases (67%), a partially matched relative in 68 cases (10%), and an unrelated volunteer in 163 patients (23%). The source of stem cells was bone marrow in 653 cases (93%), peripheral blood in 17 (2.4%) and cord blood in 32 (4.6%). Results. 167 children (24%) developed C-GVHD at a median of 115 days after HSCT (range 90-600). The 3-year Kaplan-Meier probability of developing C-GVHD was 24±2%. Extensive C-GVHD was diagnosed in 60 cases, whereas the remaining 107 patients had limited C-GVHD. 5-year survival probability of patients with C-GVHD was 67±4%. All children but 14 had previously experienced acute GVHD. Variables significantly predicting (P Ͻ 0.01) development of C-GVHD were: grade II-IV acute GVHD, recipient age Ͻ 7 yrs, female donors for male recipients, a diagnosis of malignant disease, use of TBI and donors older than 18 yrs. None of the 32 children given cord blood transplantation developed C-GVHD, as compared to 25% and 33% of patients receiving bone marrow or peripheral blood stem cells, respectively (P Ͻ 0.02). Among the 653 children given bone marrow transplantation, those receiving a cell dose Ͼ 2 x 10E8/Kg had a significantly lower probability of C-GVHD (P Ͻ 0.01). Conclusions. This study provides novel data on the risk of C-GVHD occurrence in childhood. Use of cord blood stem cells, preparative regimens without TBI, as well as better prevention of acute GVHD and infusion of a higher number of bone marrow cells, may prevent the development of this life-threatening and heavily disabling complication. JMML is a unique hematological malignancy of early childhood with myelodysplastic and myeloproliferative features. The disease is characterized by a hypersensitivity of myeloid progenitors to GM-CSF and activation of the ras signal transduction pathway by mutations of the ras or neurofibromatosis type 1 gene in about 50% of patients (pts). Chromosomal analyses of large series of pts show a normal karyotype in 63%, monosomy 7 in 28% and other abnormalities in 9%. JMML is resistant to conventional chemotherapy with a probability of survival Ͻ10% in the absence of stem cell transplantation (SCT) MUD, n=25) donor. The source of stem cells was bone marrow (n=44), peripheral blood (n=6) or cord blood (n=5). GvHD prophylaxis for transplants with MFD consisted of cyclosporin (CSA), for MUD anti-lymphocyte globulin, CSA and methothrexate was most commonly applied. At the time of analysis median follow was 13 months. 3/25 pts with a MUD transplant experienced primary graft failure, 6 pts had suffered transplant related mortality (TRM) and 14 pts had relapsed. All relapses occurred within 10 months from SCT. At 5 years, the probabilities for event-free survival (EFS), relapse and TRM were 0.60 ± 0.14, 0.31 ± 0.14 and 0.12 ± 0.09, respectively. SCT with MFD (EFS 0.69 ± 0.18) was followed by a better outcome than MUD (EFS 0.48 ± 0.21, p=0.06). There were no significant differences in EFS according to karyotype, percentage of blasts in the bone marrow or status of splenectomy. In summary, the results of this interim analysis are superior to previously published data, indicating that the preparative regimen chosen is effective for treatment of JMML.
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Factors related to prognosis in patients with primary metastatic RMS-like tumors. Analysis of the CWS-study and the German pediatric stem cell transplantation registry E. Koscielniak, T. Klingebiel, R. Knietig, M. Morgan, D. Niethammer, J. Treuner, E. Koscielniak (Stuttgart, Tuebingen, D) 201 pts with primary metastatic RMS-like (RMS, extraskeletal Ewing's sarcoma(EES),peripheral neuroectodermal tumors(PNET)), who were registered in the CWS-Study and/or the German SCT Registry, were considered for this analysis. The diagnosis was made between March 81 and January 98. The male/female ratio was 1:1. The median age at diagnosis was 10 yrs (Ͻ1-20). Primary therapy was given according to the four consecutive CWS studies . 59 pts received HDC with stem cell rescue as consolidation after achieving a CR or VGPR. The HDC used in the majority of pts consisted of melphalan alone or in combination with VP16 and carboplatin. The median time from HDC to event was 225 days (10-647), the median time from HDC to death was 342 days (10-743). 13/59 pts who received HDC are alive with a median observation time of 53 mths (25-103). 33/142 pts who did not receive HDC are alive (median follow up of 44 mths, range 5-157). Variables evaluated for their predictive effect on fatal outcome included: histology (alveolar, embryonal,EES/PNET) age (Ͻ vs =Ͼ10yrs), B/BM metastases, multiorgan metastases, induction chemotherapy (depending on study) and HDC (yes or no). In multivariate analysis age =Ͼ10 yrs (pϽ0.003) and B/BM metastases at diegnosis (pϽ0.014) were the most important predictor of fatal outcome. In pts =Ͼ10 yrs the relative risk of death was 1.33, if B/BM occurred concomitantly, the RR rose to 1.57. We conclude that pts =Ͼ10 yrs with primary B/BM metastases of RMS-like sarcoma have almost no chance of cure (5yrs SU 6%+/-4), even with HDC and a new experimental approach to therapy is necessary. Five children suffering from stage IV neuroblastoma were treated by recombinant interleukin-2 (IL-2)protocol containing 3-day cycles of subcutaneous injections of intermediate-high doses IL-2 (12 x 106 IU/m2/day) administered every 2-3 weeks, for 4-23 months post autologous peripheral blood stem cell transplantation. We monitored the levels of CD3+ and CD56+ lymphocytes, the T-cell proliferative response, and the ability of the patients' cells to kill NK-sensitive (K562), and NK-resistant (Daudi) and neuroblastoma (SKNMC or SKNSH) cell line targets. An increase in the level of total lymphocytes, which was mainly due to the expansion of T-cells, was observed. Enhanced proliferative response to PHA was evident in the 2 patients examined. Furthermore, a remarkable elevated cytotoxicity of the patients' cells against all the indicated cell line targets was detected. The clinical toxicity of the treatment was generally mild and included fever alone in 4 patients and mild to moderate encephalopathy which necessitated withdrawing one patient from the protocol. Hematological toxicity included mild reversible thrombocytopenia. Three out of five patients studied are alive today, one of them whose IL-2 was stopped, is in relapse. Two patients have died. We conclude that immunotherapy with subcutaneous intermediate-high dose Interleukin-2 is feasible and results in the expansion of T-cells and in the stimulation of killing activity against neuroblastoma tumor cells. The clinical significance of this treatment towards eradicating residual disease remains to be examined.
